SUBSCRIBE
SUBSCRIBE

Phase I

Roche Slammed With Partial Holds for Two Combo Cancer Trials
Drug Development
FDA Calls Roche’s Leukemia Drug a Breakthrough
July 28, 2017
 · 
2 min read
Drug Development
Drinking Alcohol After Studying Can Improve Memory, Scientific Reports Reveals
July 27, 2017
 · 
1 min read
Drug Development
Amgen Falls After Earnings Update Reveals Embarassingly ‘Bare’ Pipeline
July 26, 2017
 · 
2 min read
How Eli Lilly Allegedly Used a Fake Rule and Fake News to Protect Bad Patents
Drug Development
Eli Lilly Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs
July 25, 2017
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline
July 24, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End
July 24, 2017
 · 
3 min read
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer
Drug Development
10 Biotechs Tackling Senator John McCain’s Form of Aggressive Brain Cancer
July 21, 2017
 · 
3 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Drug Development
Kite Pharma Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy
July 20, 2017
 · 
3 min read
Roche Slammed With Partial Holds for Two Combo Cancer Trials
Drug Development
Uncertainty Hits as Roche is Dealt Multiple Clinical Trial Setbacks
July 19, 2017
 · 
3 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
Vertex Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials
July 19, 2017
 · 
3 min read
Load More
PRESS RELEASES
Drug Development
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
June 15, 2023
 · 
4 min read
Drug Development
EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
June 14, 2023
 · 
5 min read
Drug Development
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
June 14, 2023
 · 
1 min read
Drug Development
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
June 14, 2023
 · 
13 min read
Drug Development
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
June 14, 2023
 · 
5 min read
Drug Development
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
June 14, 2023
 · 
7 min read
Drug Development
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023
 · 
8 min read
Drug Development
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
June 13, 2023
 · 
3 min read
Drug Development
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
June 13, 2023
 · 
8 min read
Drug Development
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
June 13, 2023
 · 
2 min read
Drug Development
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
June 13, 2023
 · 
3 min read
Drug Development
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
June 13, 2023
 · 
7 min read
Drug Development
Alladapt Immunotherapeutics Announces Topline Pediatric Data from Phase 1/2 Harmony Study Evaluating ADP101 for the Treatment of Patients with Mono- and Multi-Food Allergy, as Presented at the EAACI Hybrid Congress
June 13, 2023
 · 
7 min read
Drug Development
HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
June 13, 2023
 · 
3 min read
Drug Development
Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study
June 13, 2023
 · 
3 min read
Drug Development
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
June 12, 2023
 · 
15 min read
Drug Development
Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
June 12, 2023
 · 
4 min read
Drug Development
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World’s First Oral Epothilone Anti-Cancer Drug
June 12, 2023
 · 
5 min read
Drug Development
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 12, 2023
 · 
8 min read
Drug Development
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
June 12, 2023
 · 
8 min read
Load More